GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (STU:6GJ) » Definitions » Cyclically Adjusted PS Ratio

Glaukos (STU:6GJ) Cyclically Adjusted PS Ratio : 18.26 (As of Jun. 17, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Glaukos Cyclically Adjusted PS Ratio?

As of today (2024-06-17), Glaukos's current share price is €103.00. Glaukos's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €5.64. Glaukos's Cyclically Adjusted PS Ratio for today is 18.26.

The historical rank and industry rank for Glaukos's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:6GJ' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 9.92   Med: 14.58   Max: 18
Current: 17.78

During the past years, Glaukos's highest Cyclically Adjusted PS Ratio was 18.00. The lowest was 9.92. And the median was 14.58.

STU:6GJ's Cyclically Adjusted PS Ratio is ranked worse than
94.97% of 477 companies
in the Medical Devices & Instruments industry
Industry Median: 2.13 vs STU:6GJ: 17.78

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Glaukos's adjusted revenue per share data for the three months ended in Mar. 2024 was €1.589. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €5.64 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Glaukos Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Glaukos's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glaukos Cyclically Adjusted PS Ratio Chart

Glaukos Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 13.05

Glaukos Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 12.34 13.05 14.89

Competitive Comparison of Glaukos's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, Glaukos's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glaukos's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Glaukos's Cyclically Adjusted PS Ratio falls into.



Glaukos Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Glaukos's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=103.00/5.64
=18.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glaukos's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Glaukos's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.589/131.7762*131.7762
=1.589

Current CPI (Mar. 2024) = 131.7762.

Glaukos Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.328 100.560 0.430
201409 0.378 100.428 0.496
201412 0.460 99.070 0.612
201503 0.456 99.621 0.603
201506 5.432 100.684 7.109
201509 0.529 100.392 0.694
201512 0.578 99.792 0.763
201603 0.580 100.470 0.761
201606 0.702 101.688 0.910
201609 0.712 101.861 0.921
201612 0.849 101.863 1.098
201703 0.890 102.862 1.140
201706 1.071 103.349 1.366
201709 0.900 104.136 1.139
201712 1.018 104.011 1.290
201803 0.939 105.290 1.175
201806 1.057 106.317 1.310
201809 1.059 106.507 1.310
201812 1.319 105.998 1.640
201903 1.321 107.251 1.623
201906 1.422 108.070 1.734
201909 1.442 108.329 1.754
201912 1.076 108.420 1.308
202003 1.144 108.902 1.384
202006 0.632 108.767 0.766
202009 1.231 109.815 1.477
202012 1.335 109.897 1.601
202103 1.249 111.754 1.473
202106 1.400 114.631 1.609
202109 1.288 115.734 1.467
202112 1.381 117.630 1.547
202203 1.241 121.301 1.348
202206 1.452 125.017 1.531
202209 1.512 125.227 1.591
202212 1.408 125.222 1.482
202303 1.442 127.348 1.492
202306 1.537 128.729 1.573
202309 1.502 129.860 1.524
202312 1.545 129.419 1.573
202403 1.589 131.776 1.589

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Glaukos  (STU:6GJ) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Glaukos Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Glaukos's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Glaukos (STU:6GJ) Business Description

Traded in Other Exchanges
Address
One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

Glaukos (STU:6GJ) Headlines

No Headlines